Your browser doesn't support javascript.
loading
Test accuracy of faecal calprotectin for inflammatory bowel disease in UK primary care: a retrospective cohort study of the IMRD-UK data.
Freeman, Karoline; Taylor-Phillips, Sian; Willis, Brian H; Ryan, Ronan; Clarke, Aileen.
Afiliação
  • Freeman K; Warwick Medical School, University of Warwick, Coventry, UK K.Freeman@warwick.ac.uk.
  • Taylor-Phillips S; Warwick Medical School, University of Warwick, Coventry, UK.
  • Willis BH; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Ryan R; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Clarke A; Warwick Medical School, University of Warwick, Coventry, UK.
BMJ Open ; 11(2): e044177, 2021 02 22.
Article em En | MEDLINE | ID: mdl-33619196
ABSTRACT

OBJECTIVE:

To estimate the test accuracy of faecal calprotectin (FC) for inflammatory bowel disease (IBD) in the primary care setting using routine electronic health records.

DESIGN:

Retrospective cohort test accuracy study.

SETTING:

UK primary care.

PARTICIPANTS:

5970 patients (≥18 years) without a previous IBD diagnosis and with a first FC test between 1 January 2006 and 31 December 2016. We excluded multiple tests and tests without numeric results in units of µg/g. INTERVENTION FC testing for the diagnosis of IBD. Disease status was confirmed by a recorded diagnostic code and/or a drug code of an IBD-specific medication at three time points after the FC test date. MAIN OUTCOME

MEASURES:

Sensitivity, specificity, and positive and negative predictive values for the differential of IBD versus non-IBD and IBD versus irritable bowel syndrome (IBS) at the 50 and 100 µg/g thresholds.

RESULTS:

5970 patients met the inclusion criteria and had at least 6 months of follow-up data after FC testing. 1897 had an IBS diagnosis, 208 had an IBD diagnosis, 31 had a colorectal cancer diagnosis, 80 had more than one diagnosis and 3754 had no subsequent diagnosis. Sensitivity, specificity, and positive and negative predictive values were 92.9% (88.6% to 95.6%), 61.5% (60.2% to 62.7%), 8.1% (7.1% to 9.2%) and 99.6% (99.3% to 99.7%), respectively, at the threshold of 50 µg/g. Raising the threshold to 100 µg/g missed less than 7% additional IBD cases. Longer follow-up had no effect on test accuracy. Overall, uncertainty was greater for specificity than sensitivity. General practitioners' (GPs') referral decisions did not follow the anticipated clinical pathways in national guidance.

CONCLUSIONS:

GPs can be confident in excluding IBD on the basis of a negative FC test in a population with low pretest risk but should interpret a positive test with caution. The applicability of national guidance to general practice needs to be improved.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Complexo Antígeno L1 Leucocitário Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: BMJ Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Inflamatórias Intestinais / Complexo Antígeno L1 Leucocitário Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: BMJ Open Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido